Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival -



  Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy
Designation, Positive Results, and Drug Revival - Research Report on Johnson &
                   Johnson, Lilly, GSK, Kythera, and Sanofi

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, September 20, 2013

NEW YORK, September 20, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc
(NYSE: GSK), KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH), and Sanofi
(NYSE: SNY). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On September 17, 2013, Johnson & Johnson announced that it will host its Q3
2013 conference call on October 15, 2013 at 8:30 a.m. ET. The Company reported
that the call will be hosted by Michel Orsinger, Worldwide Chairman of DePuy
Synthes Companies; Dominic J. Caruso, Vice President, Finance and Chief
Financial Officer; and Louise Mehrotra, Vice President, Investor Relations.
According to Johnson & Johnson, interested parties may access the conference
call through its Investor Relations website, mobile application for iPad and
iPhone users, and telephone by using the dial-in details. The Full Research
Report on Johnson & Johnson - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-17/JNJ]

--

Eli Lilly and Company Research Report

On September 17, 2013, Eli Lilly and Company (Lilly) announced that it will
present a total of 31 abstracts during the upcoming 49th European Association
for the Study of Diabetes Annual Meeting in Barcelona, taking place from
September 23 to September 27, 2013. According to Lilly, it will present the
Phase III data for dulaglutide (investigational GLP-1 receptor agonist) and
the Phase II data for LY2605541 (investigational novel basal insulin analog)
in seven presentations. The Company also reported that it will present an
additional seven abstracts, including research from its early-stage pipeline,
while the Boehringer Ingelheim will present seventeen abstracts on behalf of
the Alliance with Lilly. The Full Research Report on Eli Lilly and Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-17/LLY]

--

GlaxoSmithKline plc Research Report

On September 13, 2013, GlaxoSmithKline plc (GSK) and Genmab A/S announced that
the US Food and Drug Administration (FDA) has granted Arzerra (ofatumumab) a
Breakthrough Therapy designation. GSK reported that the designation was
specifically for Arzerra in combination with chlorambucil for the treatment of
chronic lymphocytic leukaemia (CLL) patients who have not received prior
treatment and are inappropriate for fludarabine-based therapy. Dr. Kathy
Rouan, Vice President and Head of Biopharmaceutical Development at GSK stated,
"We are exceedingly proud to receive the Breakthrough Therapy designation, the
second this year for GSK. This FDA programme is intended to expedite not just
the development but also the review of drugs for serious or life threatening
conditions. We are actively working on our submission and look forward to the
enhanced regulatory interaction allowed for Breakthrough Therapies." The Full
Research Report on GlaxoSmithKline plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.InvestorsReports.com/report/2013-09-17/GSK]

--

KYTHERA Biopharmaceuticals, Inc. Research Report

On September 16, 2013, KYTHERA Biopharmaceuticals, Inc. (Kythera) announced
that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and
secondary endpoints. According to the Company, the Phase III trials were
conducted in the US and Canada to compare the efficacy and safety of a 2
mg/cm^[^2^] dose of ATX-101 versus placebo for the reduction of submental fat,
which commonly presents as a double chin. Frederick Beddingfield, III, M.D.,
Ph.D., Chief Medical Officer of Kythera, stated, "The strong results from
REFINE-1 and REFINE-2 are incredibly exciting and consistent with the profile
of ATX-101 based on previous data." Beddingfield continued, "We look forward
to discussing submission plans with U.S. and Canadian regulatory authorities
in the near future. If approved, ATX-101 will represent a significant
innovation in the category of aesthetic medicine." The Full Research Report on
KYTHERA Biopharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-17/KYTH]

--

Sanofi Research Report

On September 16, 2013, Sanofi announced that Sanofi US and its consumer health
business Chattem, Inc. (Chattem) re-introduced Rolaids® in the US after a gap
of three years. According to Sanofi, the re-launch follows Chattem's
acquisition of Rolaids from McNeil Consumer Healthcare Division of McNEIL-PPC,
Inc., which was completed on January, 7, 2013. Zan Guerry, CEO of Chattem,
said, "For the last few years there has been a significant gap in the
over-the-counter antacid marketplace here in the U.S. Starting today, the
millions of people who suffer from frequent heartburn and acid indigestion can
once again turn to Rolaids to help relieve their symptoms." Anne Whitaker,
President of North America Pharmaceuticals, Sanofi, commented, "Incorporating
Rolaids into Chattem's portfolio further strengthens Sanofi's position as a
leader in the U.S. consumer healthcare sector and helps to further diversify
our category offerings." The Full Research Report on Sanofi - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-17/SNY]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders ; +1-315-982-6420 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement